ArriVent BioPharma, Inc.
AVBP$763M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNEWTOWN SQUARE52 employees
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 10, 2026
7wMarket Overview
Stock performance and key metrics
AVBP News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
furmonertinib 240 mg oral, daily
Metastatic Non-Small Cell Lung Cancer
Firmonertinib
Non-Small-Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
furmonertinib 240 mg oral, daily | Phase 3 | Metastatic Non-Small Cell Lung Cancer | - | - |
Firmonertinib | Phase 3 | Non-Small-Cell Lung Cancer | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply